Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site

Medical Oncology

Volumn 18, Issue 1, 2001, Pages 23-32

  Karapetis, C S ^a   Yip, D ^a   Virik, K ^a   Strickland, A ^a   Ryder, K ^a   Cowling, M ^a   Harper, P G ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Antineoplastic agents; CA19.9 antigen; Neoplasms; Unknown primary

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; INTRAVENOUS CATHETER; LEUKOPENIA; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CARCINOMA; CISPLATIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034801590     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:18:1:23     Document Type: Article

References (42)

1. Cancer of unknown primary site
2. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin
3. Unknown primary adenocarcinoma: Incidence of overinvestigation and natural history
4. Detection of unknown occult primary tumors using positron emission tomography
5. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)
6. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin
7. Treatment of patients with cancer of an unknown primary site
8. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: An active new regimen
9. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
10. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer
11. Infusional chemotherapy (cisplatin, epirubicin, and 5-fluorouracil, ECF) for patients with epithelial ovarian cancer (EOC)
12. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
13. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy
14. Epirubicin, cisplatin, and 5-fluoruracil in the treatment of advanced gastro-oesophageal cancer when prolonged infusional therapy is not feasible
15. Prediction of creatinine clearance from serum creatinine
16. Reporting results of cancer treatment
17. Nonparametric estimation from incomplete observations
18. Multiple significance tests: The Bonferroni method
19. Unknown primary carcinoma: Randomised studies are needed to identify optimal treatments and their benefits
20. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: Long-term results with cisplatin-based chemotherapy
21. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience
22. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
23. Treatment of the patient with adenocarcinoma of unknown origin
24. Metastatic and histologic presentations in unknown primary cancer
25. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
26. Cis-dichlorodiammineplatinum(II): Combination chemotherapy and cross-resistance studies with tumors of mice
27. Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary
28. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin
29. Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam)
30. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide
31. Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens
32. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial
33. Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin
34. Unknown primary tumors metastatic to liver
35. Evaluation of six tumor markers in patients with carcinoma of unknown primary
36. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience
37. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma?
38. Poorly differentiated carcinoma of unknown primary site: Clinical usefulness of immunoperoxidase staining
39. Epirubicin, cisplatin and intermittent continuous infusion of 5-fluorouracil in advanced gastric cancer: An effective regimen?